BlackRock, Inc. filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 338,133 shares of Monopar Therapeutics common stock, representing 5.03% of the class, based on a triggering event dated September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 338,133 shares of Monopar Therapeutics common stock.
  • Percent of class: The 338,133 shares represent 5.03% of the outstanding common stock, according to the filing.
  • Sole voting power: BlackRock reported sole voting power over 330,149 shares, with 0 shares subject to shared voting power.
  • Sole dispositive power: BlackRock reported sole dispositive power over all 338,133 shares, with 0 shares subject to shared dispositive power.
  • Triggering event date: The date of the event requiring the filing was September 30, 2026.
  • Filer type: BlackRock is identified as a parent holding company (type "HC"), incorporated in Delaware, with principal offices at 50 Hudson Yards, New York, NY 10001.

BlackRock's Schedule 13G Filing on Monopar Therapeutics Common Stock

BlackRock, Inc., a Delaware-incorporated parent holding company, filed a Schedule 13G disclosing that, as of September 30, 2026, certain of its business units beneficially owned 338,133 shares of Monopar Therapeutics (CUSIP 61023L207) common stock. The filing states that the disclosure "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates," and that it "does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units."

According to the filing, BlackRock holds sole voting power over 330,149 shares and sole dispositive power over the full 338,133 shares. Shared voting and shared dispositive power are each reported as zero. The 338,133 shares represent 5.03% of the class, as stated in the filing. No single person's interest in Monopar Therapeutics common stock among those with the right to receive dividends or proceeds from a sale is reported to exceed five percent of total outstanding common shares.

The filing certifies, as signed by Spencer Fleming, Managing Director of BlackRock, Inc., on October 27, 2026, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The identity and classification of the relevant subsidiary are provided in Exhibit 99. Monopar Therapeutics is headquartered at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.

What Was Disclosed

BlackRock, Inc. disclosed through a Schedule 13G that its reporting business units beneficially owned 338,133 shares, or 5.03%, of Monopar Therapeutics common stock as of September 30, 2026, with sole dispositive power over all reported shares and sole voting power over 330,149 shares.